Spiramycin treatment of Toxoplasma gondii infection in pregnant women impairs the production and the avidity maturation of T. gondii-specific immunoglobulin G antibodies.
The aim of the study was to evaluate the influence of treatment with spiramycin on the increase of immunoglobulin G (IgG) titers and IgG avidity indexes (AI) in pregnant women with seroconversion from the beginning of therapy until delivery and after delivery. This group was compared with adult patients with recently acquired untreated toxoplasmosis. One hundred four samples from 32 pregnant women with seroconversion for toxoplasmosis and/or very low IgG AI were followed from the beginning of therapy with spiramycin until delivery. Twenty-nine women were further followed some months after delivery and interruption of therapy. Thirty-eight samples from 16 untreated, nonpregnant patients were evaluated as the control group. The Toxoplasma gondii-specific IgG antibody and the T. gondii-specific IgG AI were significantly delayed in pregnant women receiving therapy compared to nonpregnant, untreated controls, and the findings were consistent with the results of assays from two different manufacturers. The T. gondii-specific IgG AI increased in pregnant women after they gave birth. Avidity maturation is delayed during pregnancy and treatment, and low-avidity antibodies in pregnant women within 3 to 4 months cannot be taken as a sign of infection.
Meroni
V
V
Department of Infectious Diseases, University of Pavia, Pavia, Italy. v.meroni@smatteo.pv.it
Genco
F
F
Tinelli
C
C
Lanzarini
P
P
Bollani
L
L
Stronati
M
M
Petersen
E
E
D000328:Adult; D000913:Antibodies, Protozoan / Q000096:biosynthesis*; D000915:Antibody Affinity; D000918:Antibody Specificity; D016022:Case-Control Studies; D003049:Coccidiostats / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000276:immunology*; D015572:Spiramycin / Q000627:therapeutic use*; D013997:Time Factors; D014122:Toxoplasma / Q000276:immunology*; D014123:Toxoplasmosis / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology
D000913:Antibodies, Protozoan; D003049:Coccidiostats; D007074:Immunoglobulin G; D015572:Spiramycin
J Clin Microbiol. 2005 Jul;43(7):3481-3
16000484
Clin Exp Immunol. 1999 Sep;117(3):524-8
10469057
J Clin Microbiol. 1997 Aug;35(8):1972-7
9230365
J Clin Microbiol. 2003 Dec;41(12):5414-8
14662919
Eur J Clin Microbiol Infect Dis. 2006 Nov;25(11):687-93
17024503
Rev Inst Med Trop Sao Paulo. 1999 Sep-Oct;41(5):297-303
10602544
Pathol Biol (Paris). 1986 Mar;34(3):173-7
3517786
J Clin Microbiol. 2005 Apr;43(4):1570-4
15814967
Am J Obstet Gynecol. 2001 Jan;184(2):140-5
11174493
J Infect Dis. 1993 Mar;167(3):691-7
8440939
Diagn Microbiol Infect Dis. 1998 Oct;32(2):69-73
9823527
Eur J Pediatr. 2001 Sep;160(9):534-40
11585075
J Clin Microbiol. 1990 Sep;28(9):1928-33
2229374
Epidemiol Infect. 1994 Apr;112(2):399-408
8150014
Clin Diagn Lab Immunol. 2001 Sep;8(5):904-8
11527801
Clin Microbiol Infect. 1996 Aug;2(1):25-29
11866807
Clin Diagn Lab Immunol. 2000 Sep;7(5):781-7
10973455
Diagn Microbiol Infect Dis. 1998 Jan;30(1):25-30
9488827
Clin Vaccine Immunol. 2007 Mar;14(3):239-43
17202303
Pathol Biol (Paris). 1993 Feb;41(2):155-8
8327266
Clin Diagn Lab Immunol. 2000 May;7(3):384-9
10799450
J Infect Dis. 2001 Apr 15;183(8):1248-53
11262207
Clin Diagn Lab Immunol. 1999 Sep;6(5):725-8
10473525
J Clin Microbiol. 2002 Jul;40(7):2504-8
12089270
Arch Med Res. 2002 Nov-Dec;33(6):520-3
12505095
J Infect Dis. 1989 Apr;159(4):736-40
2926163
J Clin Microbiol. 1997 Jan;35(1):174-8
8968902